Literature DB >> 25549063

Intravitreal Adalimumab in Active Noninfectious Uveitis: A Pilot Study.

Rola N Hamam1, Anita W Barikian1, Rafic S Antonios1, Marwan R Abdulaal1, Ramzi M Alameddine1, Georges El Mollayess2, Ahmad M Mansour1.   

Abstract

PURPOSE: To evaluate the short-term efficacy of intravitreal adalimumab (IVA) for the treatment of eyes with active noninfectious uveitis.
METHODS: Consecutive eyes with active noninfectious uveitis were injected with IVA at 0, 2, then every 4 weeks for total of 26 weeks.
RESULTS: Six out of 7 patients (12 of 13 eyes) completed 26 weeks of treatment. One patient (1 eye) failed treatment. Seven out of 12 eyes had improvement of ≥2 ETDRS lines. Three out of three eyes had resolution of anterior chamber cells. And 9 of 10 eyes with vitreous haze had zero haze at 26 weeks. Five out of 8 eyes with macular edema had complete resolution. Median fluorescein angiography score improved from 14 to 4 on last follow-up.
CONCLUSIONS: IVA was effective in controlling the inflammation, decreasing the macular edema, and improving the best corrected visual acuity in the majority of eyes in this series.

Entities:  

Keywords:  Adalimumab; intravitreal adalimumab; noninfectious uveitis; uveitis treatment

Mesh:

Substances:

Year:  2014        PMID: 25549063     DOI: 10.3109/09273948.2014.990041

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  15 in total

1.  Outcome of Treatment of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial 2-Year Results.

Authors:  Oren Tomkins-Netzer; Susan Lightman; Lea Drye; John Kempen; Gary N Holland; Narsing A Rao; Richard J Stawell; Albert Vitale; Douglas A Jabs
Journal:  Ophthalmology       Date:  2015-09-07       Impact factor: 12.079

Review 2.  A Review of Systemic Biologics and Local Immunosuppressive Medications in Uveitis.

Authors:  Neesurg S Mehta; Parisa Emami-Naeini
Journal:  J Ophthalmic Vis Res       Date:  2022-04-29

3.  Technology allows detection of target molecules and production of biologic agents for treatment of ocular inflammatory disorders.

Authors:  Masoud Soheilian
Journal:  J Ophthalmic Vis Res       Date:  2015 Jan-Mar

Review 4.  Recent advances in managing and understanding uveitis.

Authors:  Shih-Chou Chen; Shwu-Jiuan Sheu
Journal:  F1000Res       Date:  2017-03-16

Review 5.  A Review of the Landscape of Targeted Immunomodulatory Therapies for Non-Infectious Uveitis.

Authors:  Srilakshmi M Sharma; Dun Jack Fu; Kanmin Xue
Journal:  Ophthalmol Ther       Date:  2017-11-30

Review 6.  Old and New Challenges in Uveitis Associated with Behçet's Disease.

Authors:  Julie Gueudry; Mathilde Leclercq; David Saadoun; Bahram Bodaghi
Journal:  J Clin Med       Date:  2021-05-26       Impact factor: 4.241

Review 7.  Profile of adalimumab and its potential in the treatment of uveitis.

Authors:  Stephen J Balevic; C Egla Rabinovich
Journal:  Drug Des Devel Ther       Date:  2016-09-19       Impact factor: 4.162

8.  Ocular toxicity of intravitreal golimumab in a rabbit model

Authors:  Ceren Durmaz Engin; Serap Cilaker Miçili; Osman Yilmaz; Hüsnü Alper Bağriyanik; Bekir Uğur Ergür; Fatoş Önen; Ali Osman Saatci
Journal:  Turk J Med Sci       Date:  2020-06-23       Impact factor: 0.973

9.  An experimental study to evaluate safety/toxicity of intravitreal natalizumab.

Authors:  Rohan Chawla; Madhu Nath; Laxmi Moksha; Tapas C Nag; Thirumurthy Velpandian
Journal:  Indian J Ophthalmol       Date:  2018-10       Impact factor: 1.848

10.  Uveitis Therapy With Shark Variable Novel Antigen Receptor Domains Targeting Tumor Necrosis Factor Alpha or Inducible T-Cell Costimulatory Ligand.

Authors:  Kathryn L Pepple; Leslie Wilson; Russell N Van Gelder; Marina Kovaleva; Obinna C Ubah; John Steven; Caroline J Barelle; Andrew Porter
Journal:  Transl Vis Sci Technol       Date:  2019-09-18       Impact factor: 3.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.